DisclosureWe earn commission on partner links; ranking is set by clinician-vetted methodology — not advertisers.
Editorial criteria, vetting process, and what we never accept — regardless of commission. Affiliate relationships do not influence rankings.
Read this first. Affiliate commission does not influence editorial rank. Products without partnerships routinely outscore monetized ones — see our methodology for the literal scoring weights and our disclosure for full details on every commercial relationship.
Novo Nordisk, Eli Lilly, Pfizer, and other approved-drug sponsors.
Must hold valid telemedicine licenses in every state served and disclose PA support, refills, and refund terms.
Verifiable USP <797> compliance, valid state board licensure, sterile-injectable accreditation.
Pharmacogenomic, A1C, lipid panels — must publish lab partners and turnaround SLAs.
Third-party tested, NSF or USP-verified where applicable, no clinical claims without RCT support.
We turn down ~60% of inbound partnership inquiries. These are common reasons.
No FDA pathway, no GMP oversight, no safety data — we will not promote regardless of margin.
YMYL editorial standard requires transparent refund and prescription cancellation terms.
Anecdote and influencer testimonial are not evidence. We need RCT, observational data, or FDA filing.
Berberine, fiber blends, and similar are not GLP-1 analogs. We do not accept these placements at any rate.
Trial offers that auto-convert without clear opt-out are deceptive. We decline these regardless of commission.
Email [email protected] with product name, FDA status, evidence pack, and refund policy.
Our medical board reviews clinical claims, regulatory status, and refund/cancellation terms.
If accepted, product is scored on our 6-axis rubric. Affiliate status does not influence score.
Standard CPA or rev-share terms negotiated after editorial approval. We will not adjust scoring for higher commission.
Every featured partner is re-scored quarterly. FDA label changes or safety signals trigger immediate review.
Commission rate is not visible to the editor who scores your product. Sealed-envelope review.
Every clinical claim is verified by a licensed clinician on our medical board before publication.
Errors are corrected within 5 business days and logged publicly. We do not silently retract.
If FDA flags your product post-publication, we de-rank within 24 hours. No commercial override available.
Email [email protected] with:
Response time: 5–10 business days. We review every submission but only accept ~40% of inbound inquiries.